Works matching DE "SELEGILINE"

Results: 281

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.

Published in:

Journal of Parkinson's Disease, 2016, v. 6, n. 2, p. 401, doi. 10.3233/JPD-150758

By:

Giladi, Nir;
Asgharnejad, Mahnaz;
Bauer, Lars;
Grieger, Frank;
Boroojerdi, Babak

Publication type:

Article

Case report: cold medicines cause neuroleptic malignant-like syndrome in a patient with Parkinson's disease.

Published in:

2022

By:

JiYi, Xu;
Hantao, Song;
Lijiao, Zhao;
Bin, Qin

Publication type:

Case Study

Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.

Published in:

European Journal of Clinical Pharmacology, 2020, v. 76, n. 12, p. 1731, doi. 10.1007/s00228-020-02961-6

By:

Binde, Caroline D.;
Tvete, Ingunn F.;
Gåsemyr, Jørund I.;
Natvig, Bent;
Klemp, Marianne

Publication type:

Article

Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.

Published in:

European Journal of Clinical Pharmacology, 2002, v. 58, n. 4, p. 259, doi. 10.1007/s00228-002-0469-y

By:

Palovaara, Sanna;
Anttila, Markku;
Nyman, Leena;
Laine, Kari

Publication type:

Article

Synergistic Effect of Lovastatin and Selegiline on the Differentiation of Bone Marrow Stromal Cells Into Neuron-Like Cells.

Published in:

Jentashapir Journal of Cellular & Molecular Biology, 2023, v. 14, n. 4, p. 1, doi. 10.5812/jjcmb-141092

By:

Abdanipour, Alireza;
Karami, Behnam;
Fridoni, Mohammad Javad;
Mohamadi, Momeneh;
Fakheri, Farzaneh

Publication type:

Article

Selegiline induced differentiation of rat bone marrow mesenchymal stem cells to dopaminergic neurons in vitro.

Published in:

Pharmacia (0428-0296), 2023, v. 70, n. 4, p. 959, doi. 10.3897/pharmacia.70.e107909

By:

Altememy, Dhiya;
Ghasem Kashani, Maryam Haji;
Khosravian, Pegah

Publication type:

Article

Adjuvant potential of selegiline in treating acute toxicity of aluminium phosphide in rats.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2019, v. 125, n. 1, p. 62, doi. 10.1111/bcpt.13207

By:

Maleki, Adeleh;
Rahimi, Nastaran;
Akbarfakhrabadi, Amir;
Javadian, Nina;
Dehpour, Ahmad Reza;
Amiri, Shayan;
Hosseini, Mir‐Jamal;
Abdollahi, Alireza;
Behnoush, Behnam

Publication type:

Article

NEW ANALYTICAL METHOD FOR THE MICRO-DETERMINATION OF MONOAMINE OXIDASE INHIBITOR DRUG SELEGILINE IN PHARMACEUTICAL FORMULATIONS AND URINE SAMPLES.

Published in:

International Journal of Chemical & Pharmaceutical Analysis, 2019, v. 6, n. 2, p. 1, doi. 10.21276/ijcpa

By:

Khalil, Sabry;
Farag, Hanan

Publication type:

Article

Selegiline induces adipose tissue-derived stem cells into neuron-like cells through MAPK signaling pathway.

Published in:

Physiology & Pharmacology, 2022, v. 26, n. 1, p. 79, doi. 10.52547/phypha.26.1.4

By:

Abdanipour, Alireza;
Amalavar, Maedeh;
Alipour, Mohsen;
Feizi, Hadi

Publication type:

Article

Effect of Combined Electroacupuncture and Selegiline Treatment in Alzheimer's Disease: An Animal Model.

Published in:

Frontiers in Pharmacology, 2020, v. 11, p. N.PAG, doi. 10.3389/fphar.2020.606480

By:

Cai, Mudan;
Yang, Eun Jin

Publication type:

Article

Selegiline Transdermal System: In the Treatment of Major Depressive Disorder: A Viewpoint by Thomas C. Baghai.

Published in:

2007

By:

Baghai, Thomas C.

Publication type:

Editorial

Selegiline Transdermal System: In the Treatment of Major Depressive Disorder: A Viewpoint by J. Alexander Bodkin.

Published in:

2007

By:

Bodkin, J. Alexander

Publication type:

Editorial

Selegiline Transdermal System: In the Treatment of Major Depressive Disorder.

Published in:

Drugs, 2007, v. 67, n. 2, p. 257, doi. 10.2165/00003495-200767020-00006

By:

Frampton, James E.;
Plosker, Greg L.

Publication type:

Article

Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans--a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST).

Published in:

Frontiers in Neurology, 2023, p. 01, doi. 10.3389/fneur.2023.1271640

By:

Strupp, Michael;
Churchill, Grant C.;
Naumann, Ivonne;
Mansmann, Ulrich;
Al Tawil, Amani;
Golentsova, Anastasia;
Goldschagg, Nicolina

Publication type:

Article

Dose- and application route-dependent effects of betahistine on behavioral recovery and neuroplasticity after acute unilateral labyrinthectomy in rats.

Published in:

Frontiers in Neurology, 2023, p. 1, doi. 10.3389/fneur.2023.1175481

By:

Antons, Melissa;
Lindner, Magdalena;
Eilles, Eva;
Günther, Lisa;
Delker, Astrid;
Branner, Christina;
Krämer, Anja;
Beck, Roswitha;
Oos, Rosel;
Wuehr, Max;
Ziegler, Sibylle;
Strupp, Michael;
Zwergal, Andreas

Publication type:

Article

Effects and Safety of Monoamine Oxidase-B Inhibitors for Early Parkinson's Disease: A Network Meta-Analysis.

Published in:

European Neurology, 2024, v. 87, n. 5/6, p. 273, doi. 10.1159/000541315

By:

Wang, Yaping;
Wang, Zhiyun

Publication type:

Article

Treatment of Mild Camptocormia with Selegiline in Patients with Parkinson's Disease.

Published in:

European Neurology, 2016, v. 76, n. 1/2, p. 35, doi. 10.1159/000447631

By:

Yoritaka, asako;
Mori, Hideo;
Hattori, Nobutaka

Publication type:

Article

Selegiline: past, present and future perspectives.

Published in:: European Journal of Neurology, 2002, v. 9, p. 225, doi. 10.1111/j.1468-1331.2002.tb00056.x
Publication type:: Article

Early Development of Monoamine Oxidase Inhibitors.

Published in:

Psychiatric Annals, 2014, v. 44, n. 12, p. 563, doi. 10.3928/00485713-20141208-05

By:

Klein, Donald F.;
Arden, Peter C.

Publication type:

Article

Screening of patients receiving selegiline from methamphetamine abusers using the urinary amphetamine/methamphetamine ratio.

Published in:

Thai Journal of Pharmaceutical Sciences, 2015, v. 39, n. 4, p. 161

By:

Kaewpunya, Nunthika;
Tungtananuwat, Wichirawich;
Viriyavejakul, Akravudh;
Yongpanich, Patramon;
Thong-ra-ar, Nantana;
Hosanguan, Chanchai;
Lawanprasert, Somsong

Publication type:

Article

Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease.

Published in:

Frontiers in Behavioral Neuroscience, 2017, v. 11, p. 1, doi. 10.3389/fnbeh.2017.00075

By:

Satoka Kasai;
Toru Yoshihara;
Olga Lopatina;
Katsuhiko Ishihara;
Haruhiro Higashida

Publication type:

Article

Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.

Published in:

Journal of Neural Transmission, 2023, v. 130, n. 6, p. 847, doi. 10.1007/s00702-023-02623-8

By:

Regensburger, Martin;
Ip, Chi Wang;
Kohl, Zacharias;
Schrader, Christoph;
Urban, Peter P.;
Kassubek, Jan;
Jost, Wolfgang H.

Publication type:

Article

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.

Published in:

Journal of Neural Transmission, 2022, v. 129, n. 5/6, p. 723, doi. 10.1007/s00702-022-02465-w

By:

Jost, Wolfgang H.

Publication type:

Article

Selegiline: a molecule with innovative potential.

Published in:

Journal of Neural Transmission, 2020, v. 127, n. 5, p. 831, doi. 10.1007/s00702-019-02082-0

By:

Tábi, Tamás;
Vécsei, László;
Youdim, Moussa B.;
Riederer, Peter;
Szökő, Éva

Publication type:

Article

Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.

Published in:

Journal of Neural Transmission, 2020, v. 127, n. 2, p. 131, doi. 10.1007/s00702-020-02150-w

By:

Naoi, Makoto;
Maruyama, Wakako;
Shamoto-Nagai, Masayo

Publication type:

Article

Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.

Published in:

Journal of Neural Transmission, 2017, v. 124, n. 9, p. 1055, doi. 10.1007/s00702-017-1740-9

By:

Inaba-Hasegawa, Keiko;
Shamoto-Nagai, Masayo;
Maruyama, Wakako;
Naoi, Makoto

Publication type:

Article

Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.

Published in:

Journal of Neural Transmission, 2017, v. 124, n. 6, p. 745, doi. 10.1007/s00702-017-1705-z

By:

Müller, Thomas;
Riederer, Peter;
Grünblatt, Edna

Publication type:

Article

Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.

Published in:

Journal of Neural Transmission, 2014, v. 121, n. 4, p. 379, doi. 10.1007/s00702-013-1120-z

By:

Bartl, Jasmin;
Müller, Thomas;
Grünblatt, Edna;
Gerlach, Manfred;
Riederer, Peter

Publication type:

Article

C-type natriuretic peptide in Parkinson's disease: reduced secretion and response to deprenyl.

Published in:

Journal of Neural Transmission, 2014, v. 121, n. 4, p. 371, doi. 10.1007/s00702-013-1123-9

By:

Espiner, E.;
Dalrymple-Alford, J.;
Prickett, T.;
Alamri, Y.;
Anderson, T.

Publication type:

Article

Synthesis, molecular modeling, and in vitro screening of monoamine oxidase inhibitory activities of some novel hydrazone derivatives.

Published in:

Journal of Neural Transmission, 2013, v. 120, n. 6, p. 883, doi. 10.1007/s00702-013-0968-2

By:

Salgın-Gökşen, Umut;
Gökhan-Kelekçi, Nesrin;
Yabanoglu-Çiftci, Samiye;
Yelekçi, Kemal;
Uçar, Gülberk

Publication type:

Article

Interaction of selegiline-loaded PLGA-b-PEG nanoparticles with beta-amyloid fibrils.

Published in:

Journal of Neural Transmission, 2013, v. 120, n. 6, p. 903, doi. 10.1007/s00702-013-0992-2

By:

Baysal, Ipek;
Yabanoglu-Ciftci, Samiye;
Tunc-Sarisozen, Yeliz;
Ulubayram, Kezban;
Ucar, Gulberk

Publication type:

Article

Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease.

Published in:

Journal of Neural Transmission, 2013, v. 120, n. 5, p. 761, doi. 10.1007/s00702-012-0927-3

By:

Müller, Thomas;
Hoffmann, Josef;
Dimpfel, Walter;
Oehlwein, Christian

Publication type:

Article

Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.

Published in:

Journal of Neural Transmission, 2013, v. 120, n. 3, p. 435, doi. 10.1007/s00702-012-0899-3

By:

Inaba-Hasegawa, Keiko;
Akao, Yukihiro;
Maruyama, Wakako;
Naoi, Makoto

Publication type:

Article

''70th Birthday Professor Riederer'' Induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (−)deprenyl: a way to a disease-modifying therapy?

Published in:

Journal of Neural Transmission, 2013, v. 120, n. 1, p. 83, doi. 10.1007/s00702-012-0876-x

By:

Maruyama, Wakako;
Naoi, Makoto

Publication type:

Article

Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes.

Published in:

Journal of Neural Transmission, 2012, v. 119, n. 5, p. 545, doi. 10.1007/s00702-011-0735-1

By:

Lajkó, Eszter;
Polgár, Lívia;
Láng, Orsolya;
Lengyel, József;
Kőhidai, László;
Magyar, Kálmán

Publication type:

Article

The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model.

Published in:

Journal of Neural Transmission, 2012, v. 119, n. 1, p. 25, doi. 10.1007/s00702-011-0666-x

By:

Bekesi, Gabor;
Tulassay, Zsolt;
Lengyel, Gabriella;
Schaff, Zsuzsa;
Szombath, Dezso;
Stark, Julia;
Marczell, Istvan;
Nagy-Repas, Peter;
Adler, Ildiko;
Dinya, Elek;
Racz, Karoly;
Magyar, Kalman

Publication type:

Article

Cytoprotective effect of (−)-deprenyl, (−)desmethyl-deprenyl and (−)deprenyl- N-oxide on glutathione depleted A-2058 melanoma cells.

Published in:

Journal of Neural Transmission, 2010, v. 117, n. 6, p. 695, doi. 10.1007/s00702-010-0413-8

By:

Szende, B.;
Barna, G.;
Magyar, Kálmán

Publication type:

Article

Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain.

Published in:

Journal of Neural Transmission, 2009, v. 116, n. 11, p. 1457, doi. 10.1007/s00702-009-0225-x

By:

Weinreb, Orly;
Amit, Tamar;
Sagi, Yotam;
Drigues, Noam;
Youdim, Moussa B. H.

Publication type:

Article

Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

Published in:

Journal of Neural Transmission, 2008, v. 115, n. 1, p. 107, doi. 10.1007/s00702-007-0811-8

By:

Speiser, Z.;
Fine, T.;
Litinetsky, L.;
Eliash, S.;
Blaugrund, E.;
Cohen, S.

Publication type:

Article

Effects of selegiline on antioxidant systems in the nigrostriatum in rat.

Published in:

Journal of Neural Transmission, 2006, v. 113, n. 2, p. 151, doi. 10.1007/s00702-005-0309-1

By:

Takahata, K.;
Shimazu, S.;
Katsuki, H.;
Yoneda, F.;
Akaike, A.

Publication type:

Article

Increased cell–cell adhesion, a novel effect of R-(−)-deprenyl.

Published in:

Journal of Neural Transmission, 2005, v. 112, n. 11, p. 1433, doi. 10.1007/s00702-005-0295-3

By:

Jenei, V.;
Zor, K.;
Magyar, K.;
Jakus, J.

Publication type:

Article

Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

Published in:

American Journal of Health-System Pharmacy, 2006, v. 63, n. 10, p. 915, doi. 10.2146/ajhp050395

By:

Chen, Jack J.;
Anh-Vuong Ly

Publication type:

Article

Review: Selegiline improves symptoms and levodopa is better than pramipexole for motor function in untreated Parkinson disease.

Published in:

ACP Journal Club, 2002, v. 137, n. 2, p. 53, doi. 10.7326/acpjc-2002-137-2-053

By:

Paulseth, J. E.

Publication type:

Article

Review: Selegiline leads to a small short-term improvement in cognition and activities of daily living in Alzheimer disease.

Published in:

ACP Journal Club, 2002, v. 137, n. 1, p. 10, doi. 10.7326/acpjc-2002-137-1-010

By:

Luxenberg, Jay S.

Publication type:

Article

Deprenyl and the Relationship Between Its Effects on Spatial Memory, Oxidant Stress and Hippocampal Neurons in Aged Male Rats.

Published in:

2006

By:

Kiray, M.;
Bagriyanik, H. A.;
Pekcetin, C.;
Ergur, B. U.;
Uysal, N.;
Ozyurt, D.;
Buldan, Z.

Publication type:

Abstract

Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease.

Published in:

Journal of Neurology, 2000, v. 247, n. 11, p. 868

By:

Haapaniemi, Tarja H.;
Kallio, Mika A.;
Korpelainen, Juha T.;
Suominen, Kalervo;
Tolonen, Uolevi;
Sotaniemi, Kyösti A.;
Myllylä, Vilho V.

Publication type:

Article

Workshop II: “Neuroprotection”– the Lugano consensus.

Published in:

Journal of Neurology, 2000, v. 247, p. IV36, doi. 10.1007/PL00007774

By:

Riederer, P.;
Brücke, T.;
M&umml;ller, T.;
Schwartz, A.;
Storch, A.;
Winner, B.

Publication type:

Article

A new tetracyclic saponin from Astragalus glycyphyllos L. and its neuroprotective and hMAO-B inhibiting activity.

Published in:

Natural Product Research, 2020, v. 34, n. 4, p. 511, doi. 10.1080/14786419.2018.1491040

By:

Shkondrov, Aleksandar;
Krasteva, Ilina;
Bucar, Franz;
Kunert, Olaf;
Kondeva-Burdina, Magdalena;
Ionkovaa, Iliana

Publication type:

Article

Adverse effects of dopamine potentiation by long-term treatment with selegiline.

Published in:

Movement Disorders, 2004, v. 19, n. 1, p. 107, doi. 10.1002/mds.10641

By:

Susan Hollán;
László Vécsei;
Kálmán Magyar

Publication type:

Article

Determination of R-Deprenyl using a Maltodextrin-Based Enantioselective, Potentiometric Membrane Electrode.

Published in:

Instrumentation Science & Technology, 2007, v. 35, n. 2, p. 117, doi. 10.1080/10739140601126262

By:

Stefan‐van Staden, Raluca‐Ioana;
Mashile, Tumelo

Publication type:

Article